Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RPG Life Sciences has the GF Score of 92, which implies that the company
might have
Highest outperformance potential.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes RPG Life Sciences
might have
Highest outperformance potential.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
RPG Life Sciences (NSE:RPGLIFE) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
RPG Life Sciences GF Score Related Terms
NSE:RPGLIFE vs ZTS, UTHR: GF Score Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, RPG Life Sciences's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RPG Life Sciences GF Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, RPG Life Sciences's GF Score distribution charts can be found below:
* The bar in red indicates where RPG Life Sciences's GF Score falls into.
RPG Life Sciences (NSE:RPGLIFE) has a GF Score of 92 as of Jul. 14, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on RPG Life Sciences and its competitors. This is 12% above median its historical median of 82.00. Over the past decade, RPG Life Sciences' GF Score has ranged from 35.00 to 96.00.
Is RPG Life Sciences' GF Score too high?
RPG Life Sciences' current GF Score of 92 is 12% above median its 10-year median of 82.00. Over the past 10 years, this metric has ranged from a low of 35.00 to a high of 96.00. Overall, RPG Life Sciences has a GF Score™ of 92/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RPG Life Sciences' GF Score compare to ZTS and UTHR?
RPG Life Sciences' GF Score of 92 can be compared against companies in the Drug Manufacturers industry. Historically, RPG Life Sciences' own GF Score has ranged from 35.00 to 96.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Drug Manufacturers company?
A good GF Score depends on the Drug Manufacturers industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on RPG Life Sciences and its competitors. RPG Life Sciences's current GF Score is 92, which is 12% above median its own 10-year median of 82.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RPG Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, RPG Life Sciences (NSE:RPGLIFE) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,358.61, compared to a current price of ₹2,822.90 — trading 19.7% above its estimated fair value. The current GF Score is 92, which is 12% above median its 10-year median of 82.00. RPG Life Sciences' overall GF Score™ is 92/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For RPG Life Sciences (NSE:RPGLIFE), the current GF Score is 92 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RPG Life Sciences (NSE:RPGLIFE) Overvalued in 2026?
Based on GuruFocus' analysis, RPG Life Sciences stock appears to be overvalued.
The current stock price of ₹2,822.90 is trading 19.7% above its estimated GF Value™ of ₹2,358.61.
GuruFocus considers RPG Life Sciences to be Modestly Overvalued.
Key valuation signals for NSE:RPGLIFE:
GF Score: 92 (12% above median its 10-year median of 82.00)
GF Value™: ₹2,358.61 vs. price of ₹2,822.90 (19.7% above fair value)
No single metric tells the full story. See the NSE:RPGLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RPG Life Sciences Ltd is an integrated pharmaceutical company. Its only reportable segment is the manufacturing and marketing of pharmaceutical products. Geographically, it derives a majority of revenue from India. The company operates across Domestic Formulations, International Formulations and Active Pharmaceutical Ingredients (API). It focuses on Nephrology, Oncology, Urology, Respiratory, Gastrointestinal, Cardiovascular, Gynaecology and Pediatrics, Vitamins and Minerals, Pain Management, Neurology, Anti-Dengue, Anti-Diabetic, and Derma.
92GF Score
Get the complete analysis for NSE:RPGLIFE
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:RPGLIFE has been successfully added to your 
